Synaptogenix (NASDAQ:TAOX) Earns Sell (D-) Rating from Weiss Ratings

Synaptogenix (NASDAQ:TAOX)‘s stock had its “sell (d-)” rating reissued by stock analysts at Weiss Ratings in a note issued to investors on Saturday,Weiss Ratings reports.

Separately, Wall Street Zen lowered Synaptogenix from a “hold” rating to a “sell” rating in a research note on Saturday, August 16th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Synaptogenix has an average rating of “Sell”.

Synaptogenix Stock Performance

Shares of TAOX opened at $8.62 on Friday. The stock has a market capitalization of $30.08 million, a price-to-earnings ratio of -0.43 and a beta of 1.89. The stock has a 50 day moving average price of $6.89. Synaptogenix has a 1 year low of $1.84 and a 1 year high of $11.98.

Synaptogenix (NASDAQ:TAOX) last issued its earnings results on Friday, August 15th. The company reported ($11.26) earnings per share (EPS) for the quarter.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.